Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Merck, Occidental Petroleum, Capital One Financial, Kimberly-Clark and Allstate

Read MoreHide Full Article

For Immediate Release

Chicago, IL – June 8, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Merck (MRK - Free Report) , Occidental Petroleum (OXY - Free Report) , Capital One Financial (COF - Free Report) , Kimberly-Clark (KMB - Free Report) and Allstate (ALL - Free Report) .

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Thursday’s Analyst Blog:

Top Analyst Reports for Merck, Occidental and Capital One

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Merck, Occidental Petroleum and Capital One Financial. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Buy-ranked Merck’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry year to date, gaining +10% versus a loss of -4.0%. The Zacks analyst thinks Merck’s new products like Keytruda, Lynparza and Bridion should continue to contribute meaningfully to the top line in 2018.

Keytruda sales are gaining strong momentum with approval for additional indications especially in the first-line lung cancer setting as it is the only anti-PD-1 approved in this setting. Its Animal Health unit is also strong and remains a core growth driver for Merck.

Meanwhile, Merck will continue to focus on cost-cutting initiatives to drive the bottom line. However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competitive pressure on the diabetes franchise and on products like Isentress (HIV), Zepatier (HCV) and Zostavax (vaccine) will remain headwinds in 2018.

(You can read the full research report on Merck here >>>).

Shares of Strong Buy-ranked Occidental Petroleum have outperformed the Zacks Domestic Integrated Oil industry in the last year, gaining +47.5% vs. +43.5%. As oil prices continue to improve, Occidental Petroleum gains from more oil production in the Permian Resources and concentrating on high-margin production region.

The Zacks analyst thinks ongoing capital investment will further strengthen the existing operations of the company. The company generates stable cash flow and its Chemical plant will further improve this metric. However, Occidental Petroleum, like other oil and natural gas companies, faces the risks of cost overruns and development interruptions due to delays in drilling and other approvals.

(You can read the full research report on Occidental Petroleum here >>>).

Capital One Financial’s shares have outperformed the Zacks Consumer Loans industry in the last six months, gaining +0.7% vs. -1.1%. Further, the company has an impressive earnings surprise history, having earnings expectations in three of the trailing four quarters.

The Zacks analyst thinks that its solid liquidity position, strength in credit card and online banking businesses, higher interest rates and solid loan balance will aid growth. Also, benefits from the lower tax rates and restructuring initiatives will support its financials.

However, mounting operating expenses are likely to keep the company’s bottom line under pressure. Expenses are expected to remain high driven by the company’s business restructuring efforts. Also, deteriorating asset quality remains a major near-term concern.

(You can read the full research report on Capital One Financial here >>>).

Other noteworthy reports we are featuring today include Kimberly-Clark and Allstate.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.